The current issue of Acta Neuropathologica is devoted to transactive response DNA-binding protein-43 (TAR DNAbinding protein-43, TARDBP-43, TARDBP, or TDP-43)-related proteinopathies and contains nine papers concerning new developments in this Weld. There are four papers analyzing various aspects of TDP-43 in amyotrophic lateral sclerosis (ALS), one paper staging TDP-43 pathology in Alzheimer's disease (AD), two papers describing the experience at two diVerent institutions with TDP-43 negative frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), a paper detailing the ultrastructural features of TDP-43 positive inclusions in FTLD-U, ALS, and other neurodegenerative diseases, and a paper describing analysis of TDP-43 in plasma by ELISA.
Issue overview
The current issue of Acta Neuropathologica is devoted to transactive response DNA-binding protein-43 (TAR DNAbinding protein-43, TARDBP-43, TARDBP, or TDP-43)-related proteinopathies and contains nine papers concerning new developments in this Weld. There are four papers analyzing various aspects of TDP-43 in amyotrophic lateral sclerosis (ALS), one paper staging TDP-43 pathology in Alzheimer's disease (AD), two papers describing the experience at two diVerent institutions with TDP-43 negative frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), a paper detailing the ultrastructural features of TDP-43 positive inclusions in FTLD-U, ALS, and other neurodegenerative diseases, and a paper describing analysis of TDP-43 in plasma by ELISA.
TDP-43 in ALS, FTLD-MND, and FTLD-U: background
Molecular and pathologic progress in FTLD-U over the past 2 years has been absolutely stunning. Given the fact that FTLD-U is the single most common pathologic entity among the FTLD group [1, 2] , and that the FTLD group can be separated into the two approximately equal broad categories of tauopathies and ubiquitinopathies on the basis of the presence or absence of tau-positive or tau-negative, ubiquitin-positive inclusions [3, 4] , the signiWcance of this progress cannot be overestimated. Less than 2 years ago, the gene responsible for chromosome 17-linked FTLD-U had not been identiWed as PROGRANULIN (PGRN) and the major protein component of the ubiquitinated inclusions had yet to be identiWed as TDP-43. But in August 2006, two papers revealed that PGRN mutations are responsible for Chr17-linked FTLD-U [5, 6] , and 2 months later, two papers identiWed TDP-43 as the major protein component of inclusions in both FTLD-U and ALS [7, 8] In the early 1990s, ubiquitin-positive inclusions were described in extra-motor cortex in ALS [9] and in ALS with dementia [10] ; these were later described in frontotemporal dementia without ALS [11] , now called FTLD-U. It eventually became evident that the close clinical and pathologic relationship between ALS, or motor neuron disease (MND), and FTLD suggested that ALS, ALS with dementia or FTLD-MND, and FTLD-U without MND represented a clinicopathologic spectrum [12] . Likewise, the fact that most, if not all, cases of dementia lacking distinctive histology (DLDH) [13] were proved to be FTLD-U [1, 2, 14, 15] meant that FTLD-U was the most common underlying pathology in FTLD. The discovery that TDP-43 was the major component of the ubiquitinated inclusions in both FTLD-U and most cases of ALS linked the two at the molecular level [7, 8, [16] [17] [18] [19] [20] [21] [22] .
"Maturation" of TDP-43 positive inclusions in ALS TDP-43 is a 43-kD highly conserved and widely expressed normal nuclear protein encoded by the TARDBP gene on chromosome 1. When abnormal TDP-43 aggregates and forms cytoplasmic inclusions, normal nuclear positivity is lost. Granular cytoplasmic TDP-43 positive inclusions in neurons with absent nuclear TDP-43 labeling have been interpreted as "pre-inclusions" [16, 23, 24] . However, the paper by Mori et al. [25] in this issue suggesting that TDPpositive round inclusions develop from small dense granules whereas skein-like inclusions (SLIs) develop from "linear wisps" and that diVuse punctuate cytoplasmic staining is present in normal controls as well as in ALS cases, casts doubt upon that hypothesis. In addition, this report shows that SLIs are ultrastructurally granuloWlamentous, similar to a recent report by Hasegawa et al. [26] and in contrast to another report showing that FTLD-U cytoplasmic inclusions (CIs) are predominantly granular [24] , suggesting either that SLIs are ultrastructurally dissimilar from FTLD-U CIs or that the ultrastructural characteristics of these inclusions are yet to be completely delineated. Additionally, the paper by Lin and Dickson [27] in the current issue also shows that TDP-43 positive inclusions in both FTLD-U and ALS are predominantly granuloWlamentous and occasionally Wlamentous only but not granular only. This paper also shows similar inclusions occasionally associated with neuroWbrillary tangles in AD, Pick bodies in Pick disease, and alpha-synuclein Wlaments in Lewy bodies and Lewy neurites in Lewy body disease, which may explain the occasional immunolabeling of these inclusions with TDP-43.
TDP-43 positive inclusions in ALS-protective or toxic?
The functions of TDP-43 are diverse and incompletely understood. However, TDP-43 appears to bind to DNA, RNA, and protein. In FTLD-U, TDP-43 is abnormally phosphorylated, ubiquitinated, and enzymatically hydrolyzed in a manner that produces two abnormal C-terminal products of 23 and 27 kD [7] . What remains unclear is what that molecular evidence reveals about the pathophysiology of FTLD-U and ALS. Some insight was gained from papers showing that lower motor neurons in ALS with Golgi apparatus fragmentation had TDP-43 positive cytoplasmic inclusions, suggesting that abnormalities in TDP-43 are associated with dysfunction of neuronal secretory pathways [28] , that TDP-43 binds to and possibly stabilizes human low molecular weight neuroWlament mRNA within the nucleus and possibly during nuclear-cytoplasmic transport [29] , and that TDP-43 does not label the ubiquitin-positive lower motor neuron inclusions in familial ALS cases with SOD1 mutations [30, 31] . Because mutants of human and Drosophila TDP-43 that lack the C-terminal domain are unable to aVect splicing [32] , and because the C-terminal fragments are aggregated in the urea soluble fraction of human brain homogenates, it seemed likely that TDP-43 aggregates result in loss of function rather than a toxic gain of function. The paper by Pamphlett and Jew [33] in this issue casts doubt on that hypothesis, presenting evidence that TDP-43 positive inclusions do not protect motor neurons from neuronophagia in ALS. Supporting the concept that TDP-43 aggregates may be toxic is an exciting report of a recently developed yeast TDP-43 proteinopathy model that remarkably recapitulates many of the features of human TDP-43 proteinopathy-including nuclear localization and cytoplasmic aggregation, with growth inhibition resulting from aggregation of TDP-43 [34] .
TDP-43 processing in neurons and glia in ALS and FTLD-MND
Additional data suggest that TDP-43 also resides in the dendritic processing body of somatodendrites, in the form of RNA granules that colocalize with the postsynaptic protein PSD95, where it acts as a translational repressor and thus likely helps regulate neuronal plasticity [35] . It is noteworthy that Lin and Dickson [27] detected TDP-43 positive immunogold-labeled Wlaments in neuronal processes that appear to be dendrites. There is evidence that there are region-speciWc pathways of TDP-43 processing, in that TDP-43 positive inclusions in neocortex and hippocampus are enriched in C-terminal fragments while spinal cord inclusions appear to be composed of full-length TDP-43 [36] . Widespread neuronal and glial TDP-43 pathology is found in ALS, and interestingly, neuronal TDP-43 positive inclusions are almost all ubiquitinated while white matter glial inclusions are generally not [37] . The studies by Nishihira et al. [38] and Hiji et al. [39] in this issue look in further detail into the distribution and immunohistochemical labeling pattern of TDP-43 positive inclusions in FTLD-MND and ALS. Nishihira et al. [38] show two types of TDP-43 immunohistochemical patterns-type (1) widespread cortical and subcortical inclusions, and type (2) inclusions predominantly in motor regions, and show a signiWcant correlation of the type 1 pattern with dementia (FTLD-MND) that is not aVected by long-term artiWcial respiratory support. Likewise, Hiji et al. show that subcortical white matter inclusions are found diVusely in FTLD-MND, while white matter inclusions in ALS appear to be restricted to motor regions. As previously reported, they also found that while these glial inclusions label with antibodies to both TDP-43 and p62, they are not ubiquitinated. The Hiji et al. [39] study may explain the absence of ubiquitination of white matter inclusions: they show that biochemically, TDP-43 in white matter is diVerent from TDP-43 in gray matter, in that it is apparently not cleaved, but formed of full-length TDP-43, suggesting that ubiquitination of TDP-43 occurs only after cleavage, and also supporting the hypothesis above of region-speciWc processing pathways. This diVers, however, from another report that TDP-43 is hyperphosphorylated and truncated in white matter just as it is in gray matter [40] . On the other hand, another report suggests something completely diVerent using "deconvolution imaging" with TDP-43 and ubiquitin antibodies: that TDP-43 is not even the major ubiquitinated protein in ALS [41] . Whether TDP-43 in white matter is cleaved or full length and whether the major ubiquitinated protein in ALS is truly TDP-43 need further study.
TDP-43 in other neurodegenerative disorders
Likewise, there is conXicting information in the literature with regard to whether TDP-43 is present in other neurodegenerative disorders. One paper reported TDP-43 positivity in most FTLD-U and FTLD-MND cases, including all familial cases with mutations in PGRN, valosin-containing protein VCP, and linkage to chromosome 9p without VCP mutations, but no TDP-43 positivity in cases of FTLD-U with mutations in CHMP2B, or in cases of AD, diVuse Lewy body disease (DLBD), a variety of tauopathies (Pick disease, corticobasal degeneration, progressive supranuclear palsy, and argyrophilic grain disease [24] . Others have also found no TDP-43 positive inclusions in pure DLBD [42] . However, still others have reported TDP-43 positive inclusions in up to 30% of AD, in combined AD-DLBD, in pure DLBD, in the dentate fascia in 70% of hippocampal sclerosis cases [42] [43] [44] [45] , in some cases of Pick disease [8, 46] , in AD and CBD but not in other tauopathies [47] , and in most cases of Guamanian ALS-parkinsonismdementia complex [48, 49] . Interestingly, in an immunohistochemical analysis of TDP-43 in Wve cases of PPA with AD pathology, which might be expected to have concomitant TDP-43 positive inclusions, none did; all had AD pathology only [50] . On the other hand, one of the papers in the current issue [51] documents the distribution of TDP-43 pathology in 29 cases of AD previously shown to have TDP-43 pathology [43] . All cases were Braak and Braak stage V or VI. Three stages of TDP-43 pathology were identiWed: (1) amygdala only (six cases), (2) amygdala and hippocampus only (seven cases), and (3) amygdala, hippocampus, and neocortex. Authors suggest that these stages are comparable to Braak and Braak tangle or Lewy body stages. No cases had CIs in the hypoglossal nucleus, making the possibility of combined AD and ALS unlikely. Interestingly, the cases with mixed pathology had more severe clinical phenotypes. The authors recommend that in evaluating cases of AD for TDP-43 pathology, multiple brain regions need to be examined. Clearly, however, the literature contains conXicting reports and additional work remains to be done.
TDP-43 negative FTLD-U
Additionally, there appears to be a subset of FTLD-U cases that are TDP-43 negative [24, 52] that some are calling "atypical FTLD-U." In the current issue, there are two additional papers detailing the clinical and pathologic Wndings in cases of "atypical FTLD-U" from two separate centers: (1) Mayo Jacksonville [53] and (2) Ludwig-Maximilians University in Munich [54] . In the Mayo series, 3 of 44 FTLD-U cases were positive for ubiquitin and p62 but negative for TDP-43. Two patients presented with behavioral variant FTLD at young ages, one with a positive family history; one presented with corticobasal syndrome. There were no neuronal intranuclear inclusions (NIIs). EM showed granuloWlamentous inclusions similar to those demonstrated in SLIs in ALS [25] and in TDP-43 immuno-labeled inclusions in FTLD-U and ALS [27], again in contrast to the granular inclusions previously reported in FTLD-U [24]. In the Munich series, 9 of 44 FTLD-U cases were positive for ubiquitin and p62 and negative for TDP-43. These were all sporadic with early onset. All had hippocampal sclerosis and all had unusual curved or twisted NIIs that were negative for p62. Biochemical analysis showed that all cases had normal full-length TDP-43. So while there are several reports on "atypical FTLD-U," there are diVerent Wndings from diVerent groups. Those working in this Weld, however, know that TDP-43 immunohistochemistry is Wnicky, that diVerent techniques produce diVerent results, and that this must be considered when evaluating conclusions.
TDP-43 mutations
Some of the most exciting recent news is that TDP-43 mutations have been reported in cases of familial and sporadic ALS [55] [56] [57] [58] . These cases more closely parallel the situation in most inherited neurodegenerative disorders in which mutations are found in genes coding for the aggregating abnormal protein, and give additional credibility to reports that the identity of the major abnormal protein, at least in ALS, is TDP-43. Although to date there have been no mutations reported in FTLD [59, 60] , this news cannot be far behind.
Blood test for FTLD-U?
The remaining paper from this issue to be discussed, by Foulds et al. [61] is potentially the most exciting. This group analyzed TDP-43 in plasma using ELISA. Results showed elevated levels in 46% of clinically diagnosed FTLD, the approximate percentage of FTLD cases that have FTLD-U, and 22% of clinically diagnosed probable AD, the approximate percentage of cases of AD that have TDP-43 positive inclusions, compared to 8% of control subjects. The same results now remain to be demonstrated in antemortem plasma samples from pathologically proven FTLD-U. If this were to produce similar results, FTLD-U would be the Wrst neurodegenerative disease for which there is a blood test. IdentiWcation of patients likely to respond to eventual targeted therapies is crucial and this may be the Wrst step toward such a test.
Conclusions
These are exciting times in FTLD research, with progress beginning to catch up to that reached in AD 15 years ago. Hypotheses can now be developed and tested and the pace is frantic. The authors of the papers in this issue of Acta Neuropathologica generously add to the body of knowledge about TDP-43 and its role in FTLD. 
